Larimar Therapeutics Inc

NASDAQ:LRMR   3:59:54 PM EDT
2.76
+0.02 (+0.73%)
Earnings Announcements

Larimar Therapeutics Reports First Quarter 2022 Operating And Financial Results

Published: 05/12/2022 11:10 GMT
Larimar Therapeutics Inc (LRMR) - Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results.
Q1 Loss per Share $0.49.
Cash at March 31, 2022 of $62.6 Million Provides Projected Cash Runway Into Q3 of 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.57

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.54

More details on our Analysts Page.